Home LiteratureArticle Details
PMID: 9607931 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia.

The Journal of experimental medicine ·Vol. 187 ·No. 11 ·1998-06-01 ·Pages 1921-6

Sparer TE, Matthews S, Hussell T, Rae AJ, Garcia-Barreno B, Melero JA, Openshaw PJ

Abstract

In a murine model of respiratory syncytial virus disease, prior sensitization to the attachment glycoprotein (G) leads to pulmonary eosinophilia and enhanced illness. Three different approaches were taken to dissect the region of G responsible for enhanced disease and protection against challenge. First, mutant viruses, containing frameshifts that altered the COOH terminus of the G protein, were used to challenge mice sensitized by scarification with recombinant vaccinia virus (rVV) expressing wild-type G. Second, cDNA expressing these mutated G proteins were expressed by rVV and used to vaccinate mice before challenge with wild-type respiratory syncytial virus (RSV). These studies identified residues 193-205 to be responsible for G-induced weight loss and lung eosinophilia and showed that this region was not was not necessary for induction of protective immunity. Third, mice were sensitized using an rVV that expressed only amino acids 124-203 of the G protein. Upon RSV challenge, mice sensitized with this rVV developed enhanced weight loss and eosinophilia. This is the first time that a region within RSV (amino acids 193-203) has been shown to be responsible for induction of lung eosinophilia and disease enhancement. Moreover, we now show that it is possible to induce protective immunity with an altered G protein without inducing a pathological response.

MeSH Terms
Animals Chromosome Mapping Eosinophilia/chemically induced Female HN Protein Humans Lung/immunology Mice Mice, Inbred BALB C Mutagenesis Respiratory Syncytial Virus Infections/prevention & control Respiratory Syncytial Virus, Human/immunology Tumor Cells, Cultured Vaccinia virus Viral Envelope Proteins Viral Proteins/genetics,immunology Viral Vaccines/genetics,immunology Weight Loss
Chemicals
HN Protein Viral Envelope Proteins Viral Proteins Viral Vaccines attachment protein G
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Sparer T E
Imperial College School of Medicine, National Heart and Lung Institute at St. Mary's, London, W2 1PG United Kingdom.
Matthews S
Hussell T
Rae A J
Garcia-Barreno B
Melero J A
Openshaw P J
References (34)
34 references, click to expand
  1. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.
    Am J Epidemiol. 1969 Apr;89(4):405-21 PMID: 4305197
  2. Respiratory syncytial virus induces selective production of the chemokine RANTES by upper airway epithelial cells.
    J Infect Dis. 1997 Mar;175(3):497-504 PMID: 9041319
  3. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.
    Am J Epidemiol. 1969 Apr;89(4):435-48 PMID: 4305199
  4. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population.
    Am J Epidemiol. 1969 Apr;89(4):449-63 PMID: 4305200
  5. Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge.
    J Virol. 1986 Nov;60(2):607-13 PMID: 3773052
  6. Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice.
    J Virol. 1987 Feb;61(2):293-301 PMID: 3806789
  7. Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen.
    J Gen Virol. 1987 Aug;68 ( Pt 8):2177-82 PMID: 3497222
  8. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus.
    J Gen Virol. 1987 Sep;68 ( Pt 9):2521-4 PMID: 3655746
  9. Frame shift mutations as a novel mechanism for the generation of neutralization resistant mutants of human respiratory syncytial virus.
    EMBO J. 1990 Dec;9(12):4181-7 PMID: 2249671
  10. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice.
    J Clin Invest. 1991 Sep;88(3):1026-33 PMID: 1909350
  11. IL-12 treatment attenuates T helper cell type 2 and B cell responses but does not improve vaccine-enhanced lung illness.
    J Immunol. 1997 Jul 1;159(1):328-34 PMID: 9200470
  12. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection.
    J Exp Med. 1997 Aug 4;186(3):421-32 PMID: 9236194
  13. CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection.
    Eur J Immunol. 1997 Dec;27(12):3341-9 PMID: 9464822
  14. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G.
    Int Immunol. 1992 Apr;4(4):493-500 PMID: 1591217
  15. CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells.
    Clin Exp Immunol. 1992 Jun;88(3):527-36 PMID: 1351433
  16. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.
    J Gen Virol. 1992 Sep;73 ( Pt 9):2225-34 PMID: 1383404
  17. Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins.
    Vaccine. 1993;11(4):431-7 PMID: 8470427
  18. Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins.
    J Immunol. 1993 Jun 15;150(12):5211-8 PMID: 8515055
  19. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.
    J Immunol. 1993 Aug 15;151(4):2032-40 PMID: 8345194
  20. Distinct types of lung disease caused by functional subsets of antiviral T cells.
    J Exp Med. 1994 Jan 1;179(1):81-9 PMID: 8270885
  21. Protective and disease-enhancing immune responses to respiratory syncytial virus.
    J Infect Dis. 1995 Jan;171(1):1-7 PMID: 7798649
  22. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids.
    J Exp Med. 1995 Mar 1;181(3):901-14 PMID: 7869050
  23. MHC ligands and peptide motifs: first listing.
    Immunogenetics. 1995;41(4):178-228 PMID: 7890324
  24. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo.
    J Exp Med. 1995 Apr 1;181(4):1569-74 PMID: 7699337
  25. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls.
    Pediatrics. 1995 Apr;95(4):500-5 PMID: 7700748
  26. Preferential recognition of hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent.
    J Virol. 1995 May;69(5):2776-85 PMID: 7535865
  27. Differential modulation of Th1- and Th2-related cytokine mRNA expression by a synthetic peptide homologous to a conserved domain within retroviral envelope protein.
    Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3611-5 PMID: 7724606
  28. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo.
    J Exp Med. 1995 Oct 1;182(4):1169-74 PMID: 7561691
  29. Immunopathological mechanisms in respiratory syncytial virus disease.
    Springer Semin Immunopathol. 1995;17(2-3):187-201 PMID: 8571168
  30. Evidence that the amino acid region 124-203 of glycoprotein G from the respiratory syncytial virus (RSV) constitutes a major part of the polypeptide domain that is involved in the protection against RSV infection.
    Antiviral Res. 1995 Dec;28(4):303-15 PMID: 8669890
  31. Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus.
    J Gen Virol. 1996 Oct;77 ( Pt 10):2447-55 PMID: 8887477
  32. Immunogenicity of JHM virus proteins: characterization of a CD4+ T cell epitope on nucleocapsid protein which induces different T-helper cell subsets.
    Virology. 1996 Nov 15;225(2):339-46 PMID: 8918920
  33. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection.
    J Virol. 1997 Jan;71(1):678-85 PMID: 8985399
  34. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.
    Am J Epidemiol. 1969 Apr;89(4):422-34 PMID: 4305198
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
1998-06-01
Pages
1921-6
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2212312
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com